Aytu BioPharma (NASDAQ:AYTU) Upgraded by Zacks Research to “Hold” Rating

Zacks Research upgraded shares of Aytu BioPharma (NASDAQ:AYTU) from a strong sell rating to a hold rating in a research report sent to investors on Thursday morning,Zacks.com reports.

Several other research analysts have also commented on AYTU. Ascendiant Capital Markets raised their price objective on Aytu BioPharma from $14.00 to $14.50 and gave the company a “buy” rating in a research report on Thursday, June 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aytu BioPharma in a research report on Monday, July 6th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $10.75.

Aytu BioPharma Stock Performance

NASDAQ:AYTU opened at $2.38 on Thursday. The company has a current ratio of 1.12, a quick ratio of 1.00 and a debt-to-equity ratio of 0.27. The firm has a market capitalization of $25.54 million, a price-to-earnings ratio of -0.52 and a beta of 0.25. The firm’s fifty day simple moving average is $2.21 and its 200 day simple moving average is $2.37. Aytu BioPharma has a twelve month low of $1.65 and a twelve month high of $3.07.

Aytu BioPharma (NASDAQ:AYTU) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.09). Aytu BioPharma had a negative return on equity of 69.93% and a negative net margin of 60.17%.The business had revenue of $12.41 million for the quarter, compared to analysts’ expectations of $12.05 million. As a group, equities research analysts expect that Aytu BioPharma will post -0.73 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. BlackRock Inc. purchased a new position in Aytu BioPharma in the second quarter valued at about $49,000. Rothschild Wealth LLC purchased a new stake in Aytu BioPharma during the 4th quarter worth approximately $52,000. Dimensional Fund Advisors LP purchased a new stake in Aytu BioPharma during the 3rd quarter worth approximately $58,000. XTX Topco Ltd acquired a new position in shares of Aytu BioPharma in the 4th quarter valued at approximately $67,000. Finally, DRW Securities LLC acquired a new position in shares of Aytu BioPharma in the 4th quarter valued at approximately $76,000. Hedge funds and other institutional investors own 33.49% of the company’s stock.

About Aytu BioPharma

Aytu BioPharma, Inc is a specialty pharmaceutical company focused on the development, licensing and commercialization of novel therapeutics to address underserved medical needs. Headquartered in Englewood, Colorado, Aytu pursues a strategy of acquiring late-stage or approved products in areas such as urology, endocrinology, women’s health, pediatric care and supportive therapies. The company leverages in-house commercialization capabilities and targeted business development to build a diversified portfolio of prescription medicines and diagnostics.

Aytu’s marketed portfolio includes Natesto, a nasal testosterone gel for treatment of male hypogonadism; ZolpiMist, a zolpidem tartrate lingual spray for the short-term treatment of insomnia; and Tuzistra XR, an extended-release cough syrup formulation indicated for relief of cough and upper respiratory symptoms.